Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Exact Sciences Corporation (EXAS : NSDQ)
 
 • Company Description   
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer. The company has developed an accurate, non-invasive, patient-friendly screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. The company is currently working on the development of additional tests for other types of cancer, with the goal of becoming a leader in cancer screening and diagnostics. Exact Sciences currently has two of the brands in cancer diagnostics, Cologuard and Oncotype DX. Cologuard Test: This is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Oncotype DX: Genomic Health's first product, the 21-gene Oncotype DX breast cancer test is used to predict the likelihood of cancer recurrence, patient survival within 10 years of diagnosis and chemotherapy benefit for early-stage patients.

Number of Employees: 7,000

 
 • Price / Volume Information   
Yesterday's Closing Price: $51.63 Daily Weekly Monthly
20 Day Moving Average: 2,628,700 shares
Shares Outstanding: 188.64 (millions)
Market Capitalization: $9,739.36 (millions)
Beta: 0.92
52 Week High: $72.83
52 Week Low: $39.97
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 16.15% 10.07%
12 Week 4.70% 13.12%
Year To Date -8.12% -4.52%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
5505 ENDEAVOR LANE
-
MADISON,WI 53719
USA
ph: 608-535-8815
fax: 608-284-5701
investorrelations@exactsciences.com http://www.exactsciences.com
 
 • General Corporate Information   
Officers
Kevin T. Conroy - President and Chief Executive Officer
Aaron Bloomer - Executive Vice President and Chief Financial Offic
Mike Barber - Director
Paul Clancy - Director
D. Scott Coward - Director

Peer Information
Exact Sciences Corporation (CORR.)
Exact Sciences Corporation (RSPI)
Exact Sciences Corporation (CGXP)
Exact Sciences Corporation (BGEN)
Exact Sciences Corporation (GTBP)
Exact Sciences Corporation (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 30063P105
SIC: 8071
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 07/30/25
Share - Related Items
Shares Outstanding: 188.64
Most Recent Split Date: (:1)
Beta: 0.92
Market Capitalization: $9,739.36 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.08 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.14 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 29.27% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/30/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 4.06
Price/Cash Flow: 9.17
Price / Sales: 3.44
EPS Growth
vs. Year Ago Period: 58.00%
vs. Previous Quarter: -250.00%
Sales Growth
vs. Year Ago Period: 10.86%
vs. Previous Quarter: -0.93%
ROE
03/31/25 - -3.75
12/31/24 - -5.29
09/30/24 - -6.17
ROA
03/31/25 - -1.68
12/31/24 - -2.45
09/30/24 - -2.98
Current Ratio
03/31/25 - 2.73
12/31/24 - 2.15
09/30/24 - 2.12
Quick Ratio
03/31/25 - 2.38
12/31/24 - 1.92
09/30/24 - 1.93
Operating Margin
03/31/25 - -3.71
12/31/24 - -5.72
09/30/24 - -7.27
Net Margin
03/31/25 - -36.06
12/31/24 - -37.29
09/30/24 - -7.95
Pre-Tax Margin
03/31/25 - -36.38
12/31/24 - -37.56
09/30/24 - -7.82
Book Value
03/31/25 - 12.71
12/31/24 - 12.98
09/30/24 - 17.38
Inventory Turnover
03/31/25 - 5.67
12/31/24 - 6.05
09/30/24 - 6.40
Debt-to-Equity
03/31/25 - 0.97
12/31/24 - 0.97
09/30/24 - 0.72
Debt-to-Capital
03/31/25 - 49.21
12/31/24 - 49.14
09/30/24 - 41.94
 

Powered by Zacks Investment Research ©